Kornitzer Capital Management Inc. KS Has $413,000 Holdings in Dynavax Technologies Co. (DVAX)

Kornitzer Capital Management Inc. KS cut its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 98.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 22,100 shares of the biopharmaceutical company’s stock after selling 1,091,645 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Dynavax Technologies were worth $413,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Cubist Systematic Strategies LLC raised its stake in Dynavax Technologies by 54.5% during the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 3,700 shares during the period. Legal & General Group Plc raised its stake in Dynavax Technologies by 18.5% during the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 1,950 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Dynavax Technologies by 474.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 5,880 shares during the period. Family Management Corp raised its stake in Dynavax Technologies by 72.7% during the second quarter. Family Management Corp now owns 19,000 shares of the biopharmaceutical company’s stock worth $183,000 after purchasing an additional 8,000 shares during the period. Finally, Royal Bank of Canada raised its stake in Dynavax Technologies by 17.0% during the second quarter. Royal Bank of Canada now owns 20,454 shares of the biopharmaceutical company’s stock worth $198,000 after purchasing an additional 2,975 shares during the period. 70.54% of the stock is currently owned by institutional investors.

Shares of Dynavax Technologies Co. (NASDAQ DVAX) opened at $17.30 on Tuesday. Dynavax Technologies Co. has a 52 week low of $3.80 and a 52 week high of $24.45.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.15. The business had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.28 million. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The business’s revenue was down 68.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.90) EPS. research analysts expect that Dynavax Technologies Co. will post -1.72 earnings per share for the current fiscal year.

A number of equities analysts have commented on the stock. Cantor Fitzgerald lifted their target price on shares of Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Thursday, November 9th. Zacks Investment Research downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. ValuEngine downgraded shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. BidaskClub downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Cowen reaffirmed a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a research note on Friday, November 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $25.17.

In other news, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total value of $141,750.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP David Louis Johnson sold 3,092 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $18.60, for a total transaction of $57,511.20. Following the completion of the sale, the vice president now directly owns 7,780 shares in the company, valued at $144,708. The disclosure for this sale can be found here. 2.90% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Kornitzer Capital Management Inc. KS Has $413,000 Holdings in Dynavax Technologies Co. (DVAX)” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2018/02/06/kornitzer-capital-management-inc-ks-has-413000-holdings-in-dynavax-technologies-co-dvax.html.

Dynavax Technologies Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply